Syndax Pharmaceuticals Inc (SNDX) Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX Healthcare · Biotechnology
Mkt Cap $1.22B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Syndax's Revuforj (revumenib) won the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases, a top honor in biopharmaceutical innovation.
Revuforj is the first and only FDA-approved menin inhibitor for relapsed/refractory NPM1-mutated AML and KMT2A-translocated acute leukemia in adults and children one year and older.
The award is a reputational milestone with no new clinical or financial data; multiple trials of revumenib in newly diagnosed patients remain ongoing.
• 2d ago AI analysis › Press Release
Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and members of the management team will participate in four investor conferences in November 2026.
Fireside chats are scheduled at the Guggenheim Healthcare Innovation Conference (Nov 10), Stifel Healthcare Conference (Nov 12), UGS Global Biopharma Conference in London (Nov 17), and Jefferies London Healthcare Conference (Nov 19).
Live webcasts and replays will be available in the investor section of the company's website. No new business or financial information was disclosed.
• 2d ago AI analysis › Press Release
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax Pharmaceuticals will report third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.
Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day, with a replay available for 90 days.
This is a scheduling notice only; no results are included in the release.
• 6d ago AI analysis › Press Release
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax's Revuforj (revumenib), the company's first-in-class menin inhibitor, was selected by TIME as one of the Best Inventions of 2026 in the Medical and Healthcare category.
Revuforj is the only FDA-approved menin inhibitor, indicated for relapsed or refractory acute leukemia with a KMT2A translocation (approved November 2024) or a susceptible NPM1 mutation (expanded October 2025).
The recognition is a marketing and awareness win with no change to approvals, financials, or guidance; modest brand value only.
• 17d ago AI analysis › Press Release ● Major ⚠ 2
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint of annualized FVC decline, and the company will not pursue further IPF development of the drug.
The 145-patient trial showed a safety profile comparable to placebo with no new safety signals, but failed on efficacy.
The company stressed the outcome does not affect ongoing axatilimab trials in chronic GVHD, with readouts expected later this year and in early 2028, including its partnership with Incyte on Niktimvo.
• 20d ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted inducement stock options to purchase up to 213,300 shares to nine new employees on October 1, 2026, under its 2023 Inducement Plan.
The awards vest over four years with a standard one-year cliff at 25%, followed by monthly vesting over 36 months, subject to continued employment.
This is routine hiring-related equity disclosure under NASDAQ Listing Rule 5635(c)(4) with no bearing on strategy or financials.
• 0mo ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted inducement stock options to purchase up to 175,000 shares of common stock to nineteen new employees on September 1, 2026.
The awards were made under the company's 2023 Inducement Plan consistent with NASDAQ Listing Rule 5635(c)(4), vesting over four years with a 25% cliff at the one-year anniversary and monthly vesting thereafter.
This is routine new-hire equity compensation with negligible dilution and no bearing on the commercial or clinical profile of the company.
• 1mo ago AI analysis › Press Release
Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team members will participate in two upcoming investor conferences in September.
The company is scheduled to attend the Citi 2026 Biopharma Back to School Conference on Sept. 10 and the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15.
Live webcasts and replays of the fireside chats will be accessible in the Investor Relations section of the Syndax website.
• 2mo ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted inducement awards for 59,250 shares of common stock to five new employees under its 2023 Inducement Plan.
The options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly thereafter.
These grants were issued in accordance with NASDAQ Listing Rule 5635(c)(4) regarding employment inducement awards.
• 2mo ago AI analysis › Press Release ● Major
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax reported second quarter 2026 total revenue of $72.8 million, a 92% increase year-over-year, driven by strong sales of Revuforj and collaboration revenue from Niktimvo.
Net product revenue for Revuforj grew 91% to $54.7 million, while Syndax's share of Niktimvo commercial profit reached $18.1 million, up 67% from the prior year.
The company reiterated its full-year 2026 expense guidance of approximately $400 million and stated that its cash position and revenue stream are expected to fund operations into profitability.
• 2mo ago AI analysis › Press Release
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals announced it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.
Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the quarterly results.
The company is a commercial-stage biopharmaceutical firm advancing innovative cancer therapies, including FDA-approved products Revuforj and Niktimvo.
• 3mo ago AI analysis › Press Release
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals unveiled two new pipeline assets, SNDX-4321 and SNDX-62122, during its R&D event, targeting NSCLC and myelofibrosis respectively.
The company expects to submit an IND for the allosteric EGFR inhibitor SNDX-4321 by the end of 2026, while the menin inhibitor SNDX-62122 is slated for IND submission and Phase 1 initiation in 2027.
Management confirmed that topline data from the Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis remains on track for the fourth quarter of 2026.
• 3mo ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted inducement awards to purchase 250,700 shares of common stock to eight new employees under its 2023 Inducement Plan.
The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter.
Syndax is a commercial-stage biopharmaceutical company focused on cancer therapies, including FDA-approved products Revuforj and Niktimvo.
• 4mo ago AI analysis › Press Release ● Major
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax presented 12 abstracts on its FDA-approved menin inhibitor Revuforj at the EHA 2026 Congress, highlighting robust activity across multiple acute leukemia subtypes.
Real-world data from the ROAR study showed an 82% overall response rate and 64% complete remission rate in heavily pretreated relapsed/refractory patients with NPM1 mutated or KMT2A-rearranged AML.
Frontline combination data revealed a 97% composite complete remission rate and 86% MRD negativity in newly diagnosed patients, while post-transplant maintenance data showed a 95% one-year overall survival rate.
• 4mo ago AI analysis › Press Release ● Major
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax published Phase 1/2 SAVE trial data for Revuforj in combination with decitabine/cedazuridine and venetoclax in relapsed/refractory AML in the Journal of Clinical Oncology.
The all-oral regimen achieved an 88% overall response rate and 60% CR/CRh rate in a heavily pretreated cohort, with 80% of responders achieving MRD negativity.
Notably, 50% of venetoclax-exposed patients achieved CR/CRh, a population with historically poor outcomes, supporting potential synergy and label expansion into newly diagnosed settings via the EVOLVE-2 and RAVEN trials.
• 4mo ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted stock options to purchase 66,700 shares to four new employees.
The awards were issued under the company's 2023 Inducement Plan to comply with NASDAQ Listing Rule 5635(c)(4).
The options vest over four years, with 25% vesting after one year and the remainder monthly thereafter.
• 4mo ago AI analysis › Press Release
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Pharmaceuticals has entered into agreements to issue $250 million of 2.25% Convertible Senior Notes due 2031.
The notes carry an initial conversion price of $24.76 per share, representing a 35% premium to the June 3 closing price, which limits immediate dilution risk.
Net proceeds of approximately $243 million will be used for general corporate purposes, including R&D and commercialization of its oncology pipeline.
• 4mo ago AI analysis › Press Release ● Major ⚠ 3
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax presented oral data at ASCO 2026 showing a 90% two-year overall survival rate for patients with acute leukemia who resumed Revuforj after stem cell transplant.
This compares favorably to a 51% historical benchmark for similar patients treated prior to the availability of menin inhibitors.
The company highlighted the clinical importance of this dataset and announced plans for the MenTain study, a randomized, placebo-controlled trial evaluating revumenib as post-transplant maintenance.
• 4mo ago AI analysis › Press Release
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Pharmaceuticals announced it will host an R&D Day on July 14, 2026, at 8:30 AM ET in New York City.
The event will feature presentations by management and key opinion leaders highlighting late-stage programs revumenib and axatilimab, as well as early-stage assets.
A live webcast and replay will be available on the company's investor website.
• 5mo ago AI analysis › Press Release
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals announced that four abstracts for its approved drug Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting.
The highlight is an oral presentation of safety and efficacy data from 21 adults and children with acute leukemia who received revumenib as maintenance therapy following hematopoietic stem cell transplantation.
Additional posters will cover pharmacokinetics, including administration with gastric acid reducing agents, and the design of ongoing Phase 3 trials in newly diagnosed patients.
• 5mo ago AI analysis › Press Release
Syndax Announces Participation in Upcoming Investor Conferences
globenewswire.com • 5mo ago Press Release ● Major ⚠ 2
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals has 12 abstracts accepted for presentation at the EHA 2026 Congress, showcasing the strong clinical activity of Revuforj (revumenib) across various stages of acute leukemia treatment.
The abstracts highlight favorable outcomes and tolerability with revumenib, particularly in the post-transplant setting and in combination with other therapies. This reinforces the drug's potential and the company's leadership in menin inhibition.
Key data from the ROAR study, a multicenter real-world study of revumenib in relapsed/refractory acute leukemia, and the Phase 1 trial of revumenib in combination with intensive chemotherapy in newly diagnosed AML patients are among the accepted abstracts.
The company also presented data from the SAVE trial, which showed high rates of MRD negativity, robust transplant rates, and favorable tolerability in relapsed/refractory AML patients.
• 5mo ago AI analysis › Press Release
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted inducement awards for 162,100 shares of common stock to eight new employees under its 2023 Inducement Plan.
The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter.
This disclosure was made in accordance with NASDAQ Listing Rule 5635(c)(4).
• 5mo ago AI analysis › Press Release ● Critical
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax reported Q1 2026 total revenue of $64.9 million, a 224% year-over-year increase, driven by strong sales of its two commercial-stage medicines.
Revuforj net revenue reached $48.9 million, up 144% from the prior year, while Niktimvo contributed $15.9 million in collaboration revenue based on $55.1 million in total product sales.
The company expects to reach profitability based on its current cash position of $352.1 million and growing product revenue, with key clinical data readouts anticipated throughout 2026.
• 6mo ago AI analysis › Press Release
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
globenewswire.com • 6mo ago 
